Walgreens Boots Alliance Immediately
Walgreens Boots Alliance
As of 03/10/2025 04:00 PM Jap
- 52-Week Vary
- $8.08
▼
$22.05
- Dividend Yield
- 8.87%
- Value Goal
- $11.54
Troubled pharmacy chain Walgreens Boots Alliance Inc. NASDAQ: WBA has been a spectacular disappointment since finishing its merging in 2014. Shares rose to a excessive of $97.14 following the union however had since fallen % to a low of $8.11 on November 21. 2024.
The retail/wholesale sector big’s try to develop into an integrated healthcare supplier because the world’s largest pharmacy chain within the medical sector fell quick because it overleveraged itself with Ceremony Assist and VillageMD acquisitions. The corporate continues to be an asset big, which can be value extra in elements than the entire. Regardless of the $11.45 per share announcement to be acquired by Sycamore Companions in a $23.7 billion deal, shareholders should nonetheless approve and may flip it down.
Alongside Got here Sycamore Companions at $11.45 Per Share
On March 6, 2025, personal fairness agency Sycamore Companions introduced its settlement to buy Walgreens Boots Alliance for $11.45 per share in money or $23.7 billion. Walgreens shares have been already buying and selling at $10.75 the earlier night, leading to a really tiny premium. The provide additionally accommodates a $3.00 Divested Asset Proceed Proper. Sycamore intends to dump a few of its property, together with Village Medical, and buyers get extra proceeds of as much as $3 per share.
A 35-Day Go Store Interval is Supplied, However 26% Dividend Awaits
Underneath the settlement with Sycamore, Walgreens is supplied with a 35-day „go store“ interval, which permits the corporate to actively pursue or settle for extra gives from different events. Centerview Companions is its monetary advisor.
To “sweeten the pot,“ Sycamore is providing the Divested Asset Proceed Proper of $3.00 per share instantly after the deal closes. Shareholders wouldn’t have to attend till they dump the Village Medical, CityMD and Summit Well being subsidiaries. This ends in a 26% one-time dividend for taking the deal. This will likely definitely tempt buyers into shopping for shares to obtain a profitable return on funding (ROI). The deal is predicted to shut within the fourth quarter of 2025.
Was This Wall Avenue’s Worst Saved Secret?
The truth that Walgreens shares have been buying and selling close to the $11.00 vary forward of the buyout announcement signifies the cat might have already gotten out of the bag because the rumors swelled. Bloomberg first reported the rumors in December 2024, and CNBC’s David Faber reported the potential for a deal in February 2025, which helped drive shares increased after bouncing off the $9.32 value stage.
For the reason that inventory is now buying and selling inside pennies of the $11.45 per share buyout, there’s a whole lot of confidence that the deal will both comply with by way of or one other purchaser might step as much as the desk. The 26% dividend is a tricky provide to stroll away from until you’re a shareholder (aka bagholder) that shares above the $14.45 value stage, of which there are a lot. There may be additionally no termination charge, so if present shareholders terminate the deal, Walgreens will get nothing.
A Turnaround Might Have Been Gaining Traction Like Rival CVS Well being
On January 10, 2025, Walgreens reported fiscal Q1 2025 earnings per share (EPS) of 51 cents, signaling that the turnaround was gaining traction. Revenues rose 7.6% year-over-year (YoY) to $39.5 billion, beating the $37.4 billion consensus analyst estimates. Its U.S. Retail Pharmacy phase noticed gross sales rise 6.6% YoY, and comparable gross sales rose 8.5% YoY. Internation gross sales rose 10.2% YoY to $6.4 billion.
Rival CVS Health Co. NYSE: CVS revealed its turnaround can also be gaining traction within the February 12, 2025, launch of its This autumn 2024 outcomes, beating consensus EPS estimates by 28 cents as revenues grew 4.2% YoY to $97.71 billion, beating $97.09 billion consensus estimates.
Its U.S. Healthcare phase noticed progress in all its companies, together with Village Medical gross sales, rising 9%, CareCentrix gross sales, rising 16%, and Protect, rising 30% YoY. The corporate reaffirmed its fiscal full 12 months 2025 steering for EPS of $1.40 to $1.80 versus $1.52 consensus estimates. Progress in its U.S. Healthcare and Worldwide gross sales ought to greater than offset the decline in its U.S. Retail Pharmacy enterprise.
The CEO Is Bought on the Acquisition
It’s value noting that Walgreen’s CEO Tim Wentworth is in favor of the deal, stating, „Sycamore will present us with the experience and expertise of a associate with a powerful observe document of profitable retail turnarounds. The WBA Board thought-about all these elements in evaluating this transaction, and we imagine this settlement gives shareholders premium money worth, with the flexibility to profit from extra worth creation going ahead from monetization of the VillageMD companies.”
Earlier than you take into account Walgreens Boots Alliance, you will wish to hear this.
MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Walgreens Boots Alliance wasn’t on the record.
Whereas Walgreens Boots Alliance at the moment has a Scale back score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
View The Five Stocks Here
Enter your e mail deal with and we’ll ship you MarketBeat’s record of the ten greatest shares to personal in 2025 and why they need to be in your portfolio.
Get This Free Report
